venetoclax

A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion; structure in first source.

Also Known As:

4- (4- ((2- (4- chlorophenyl)- 4,4- dimethylcyclohex- 1- en- 1- yl)methyl)piperazin- 1- yl)- N- ((3- nitro- 4- ((tetrahydro- 2H- pyran- 4- ylmethyl)amino)phenyl)sulfonyl)- 2- (1H- pyrrolo(2,3- b)pyridin- 5- yloxy)benzamide; ABT-199; GDC-0199; RG-7601; RG7601; Venclexta; benzamide, 4- (4- ((2- (4- chlorophenyl)- 4,4- dimethyl- 1- cyclohexen- 1- yl)methyl)- 1- piperazinyl)- n- ((3- nitro- 4- (((tetrahydro- 2h- pyran- 4- yl)methyl)amino)phenyl)sulfonyl)- 2- (1h- pyrrolo(2,3- b)pyridin- 5- yloxy)-

Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - venetoclax: 1653
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - venetoclax: 1653
Heterocyclic Compounds: 198
- Bridged-Ring Heterocyclic Compounds
  - Heterocyclic Bridged Bicyclo Compounds
    - venetoclax: 1653

Olga Bridges Selected Research

Olga Bridges Research Topics

Disease

Drug/Important Bio-Agent (IBA)